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Ginsenoside Rb1 blocks homocysteine-induced
endothelial dysfunction in porcine coronary
arteries
Wei Zhou, MD, Hong Chai, MD, PhD, Peter H. Lin, MD, Alan B. Lumsden, MD,
Qizhi Yao, MD, PhD, and Changyi Chen, MD, PhD, Houston, Tex
Objective: Homocysteine (Hcy) is an independent risk factor for atherosclerosis. This study investigates the effects of
ginsenoside Rb1, a major constituent of ginseng, on Hcy-induced endothelial dysfunction and molecular changes in
porcine coronary arteries.
Methods: The coronary arteries were harvested from pig hearts and cut into 5-mm ring segments, which were then divided
into six groups, including control, Hcy alone (50 M), low-dose (1 M) or high-dose (10 M) Rb1 alone, and Hcy plus
low-dose or high-dose Rb1. After 24-hour incubation, the rings were analyzed for vasomotor function in response to
thromboxane A2 analog U46619, bradykinin, and sodium nitroprusside (SNP), respectively. In addition, superoxide
anion was assessed by lucigenin-enhanced chemiluminescence analysis. Endothelial nitric oxide synthase (eNOS) was
studied using real-time polymerase chain reaction and Western blot.
Results: Endothelium-dependent relaxation (bradykinin) was significantly reduced in rings treated with Hcy alone as
compared with the control (49.80% vs 71.77%, n  8, P < .05), whereas neither high-dose nor low-dose Rb1 alone
affected the endothelium-dependent relaxation. The low-dose Rb1-Hcy combined group had a partially improved
endothelium-dependent relaxation (54.44%), whereas the high-dose Rb1-Hcy combined group showed a complete
recovery of endothelium-dependent relaxation (72.89%). There was no substantial difference in maximal contraction
induced by U46619 or endothelium-independent relaxation by SNP among all groups (P > .05). Furthermore,
superoxide anion was markedly increased by 137% in the Hcy-treated group as compared with the control, but there were
no statistically significant changes from the control in all other groups (P> .05). Lastly, eNOS mRNA and protein levels
were substantially reduced in the Hcy-treated group, but not in the Rb1-Hcy combined groups.
Conclusions: This is the first study to show that ginsenoside Rb1 can effectively block Hcy-induced endothelial
dysfunction and superoxide anion production as well as eNOS downregulation in porcine coronary arteries. This study
suggests that ginseng and its active constituents may have potential clinical applications in controlling Hcy-associated
vascular injuries. ( J Vasc Surg 2005;41:861-8.)
Clinical Relevance: Homocysteine (Hcy) is an independent risk factor for atherosclerosis and other vascular lesions. It
causes endothelial dysfunction and oxidative stress. Ginseng compounds have effects of vasorelaxation and antioxidation.
The purpose of this study was to determine the effect of ginsenoside Rb1, a major constituent of ginseng, onHcy-induced
endothelial dysfunction andmolecular changes in porcine coronary arteries. Our results showed that ginsenoside Rb1 can
effectively block Hcy-induced dysfunction of endothelium-dependent vasorelaxation as well as superoxide anion
production and eNOS downregulation. This study suggests that ginseng compounds may have potential clinical
applications in controlling Hcy-associated vascular diseases and other vascular lesions.Since McCulley first made the association between
homocysteine and arthrosclerosis in 1969, multiple studies
have shown that Hcy is an independent risk factor for
atherosclerotic diseases.1 Plasma homocysteine (Hcy) lev-
els correlated with cardiovascular mortality and with pe-
ripheral and coronary artery disease.2-4 A growing body of
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doi:10.1016/j.jvs.2005.01.054evidence suggests that oxidative stress plays an important
role in the effects of Hcy on the cardiovascular system. In
earlier studies, we showed that Hcy significantly impaired
endothelium-dependent vasorelaxation and decreased en-
dothelial nitric oxide synthase (eNOS) immunoreactivity in
porcine coronary arteries.5,6 It is widely accepted that en-
dothelium dysfunction is an initial step of atherosclerosis by
virtue of impairing endothelium-dependent factors, alter-
ing blood vessel permeability, and changing platelet and
leukocyte adhesions. Additionally, a strong correlation be-
tween plasma Hcy levels and the oxidative stress marked by
plasma malondialdehyde was identified in patients with
cardiovascular diseases.7
Ginseng, a widely recognized herbal drug, has been
reported to have a wide range of therapeutic and pharma-
cologic uses. Ginseng’s genus name Panax is derived from
theGreek words pan (all) and akos (cure), meaning cure-all.
Ginseng root has been used extensively in Chinese medi-
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world for its alleged tonic effect and possible curative and
restorative properties. There is increased clinical evidence
concerning the potential benefits of ginseng roots in car-
diovascular diseases. Studies have shown that the ginseng
root and ginsenosides, the major constituents of ginseng,
have protective roles in atherosclerotic plaque formation
and various vascular injuries in part because of the prevent-
ing of free-radical injury to the vascular endothelium.8,9 We
hypothesized that ginseng and its active constituents could
protect the vessels from Hcy damage. In this study, we
investigated the molecular mechanisms of and the func-
tional effects of ginsenoside Rb1 (Rb1) on Hcy-induced
endothelial dysfunction in porcine coronary arteries. The
data from our study suggest a potential clinical application
of ginseng in controlling Hcy-associated vascular injuries.
MATERIALS AND METHODS
Chemical and reagents. Hcy (DL-homocysteine), di-
methyl sulfoxide (DMSO), thromboxane A2 analog (9,
11-dideoxy-11a, 9 a-epoxymethanoprostaglandin F2a)
(U46619), bradykinin, Rb1 (from Panax quinquefolium
root, dissolved in dimethyl sulfoxide ), Tri-Reagent, tris-
buffered saline (TBS) solution, phosphate-buffered saline
(PBS) solution, antihuman -actin monoclonal antibody,
and Tween 20 were obtained from Sigma (St. Louis, MO).
Dulbecco modified Eagle medium (DMEM) was obtained
from Life Technologies, Inc (Grand Island, NY), and anti-
biotic-antimycotic was obtained from Mediatech Inc
(Herndon, VA). The iScript cDNA Synthesis Kit and iQ
SYBR Green SuperMix Kit were obtained from Bio-Rad
Laboratories (Hercules, CA). The protein assay kit and
polyacrylamide gels were obtained from Bio-Rad Labora-
tories. Antibody against human eNOS was obtained from
BD Transduction Laboratories (Lexington, KY). Horse-
radish peroxidase-conjugated goat antimouse secondary
antibodies and the enhanced chemiluminescence kit were
obtained from Amersham life Sciences (Buckinghamshire,
England). The biotinylated horse antimouse immunoglob-
ulin G and avidin-biotin complex kit were obtained from
Vector Labs (Burlingame, CA).
Isometric tension of porcine coronary arteries. The
myograph system used in our laboratory has been previ-
ously described.5,10-12 Pig hearts (n  8) were harvested
from 6- to 7-month-old farm pigs within 10 minutes of
killing at a local slaughterhouse. The right coronary artery
was harvested and cut into multiple 5-mm rings, which
were then incubated in DMEM and divided into six groups
(eight rings per group): DMSO control, Hcy alone (50
M), low-dose (1 M) or high-dose (10 M) Rb1 alone,
and Hcy plus low-dose or high-dose Rb1. After 24-hour
incubation in a 37° C and 5% CO2 cell culture incubator,
the artery rings were analyzed using myograph analysis
(Danish Myo Technology Organ Bath 700 MO, Aarhus,
Denmark). Each ring was treated with thromboxane A2
analogue U46619 (107 M) to generate maximal contrac-
tion. The dose of 107 M of U46619 was chosen because
our previous experiments showed that this was an optimaldose for the contraction of porcine coronary rings (data not
shown). A relaxation dose-response curve was generated by
adding 60 L of five cumulative doses of the endothelium-
dependent vasodilator bradykinin (109, 108, 107,
106, and 105 M) at 3-minute intervals. Bradykinin is a
potent vasodilator that acts through endothelial B2 kinin
receptors to stimulate the release of NO through eNOS
activation.13 Subsequently, endothelium-independent re-
laxation was induced by adding sodium nitroprusside
(SNP, 105 M). Contractility and percentage of relaxation
were calculated based on the tension changes. The data of
the coronary artery rings from eight different pig hearts
were averaged and represented as one data point for statis-
tical analysis.
Real-time polymerase chain reaction (PCR). The
porcine coronary artery endothelial cells were collected
from cultured artery rings by scraping the luminal surface
with surgical blades. Total RNA from cultured porcine
coronary artery endothelial cells was isolated by using Tri-
Reagent following the manufacturer’s instructions. cDNA
was generated by reverse transcript from mRNA using the
iScript cDNA Synthesis Kit according to the manufactur-
er’s instructions. The iQ SYBR Green SuperMix Kit was
then used for real-time PCR reaction. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a housekeeping
gene, was used as internal control for eNOS expression to
account for variations in mRNA loading. The same total
RNA, 1 g, was loaded for all samples. Porcine eNOS and
GAPDH primers were designed using Beacon Designer.
The eNOS (GenBank no. AY266137) primer sequences
are: forward primer 5’-CCCTACAACGGCTCCCCTC-3’
and reverse primer 5’-GCTGTCTGTGTTACTGGATTC-
CTT-3’. The GAPDH (GenBank no. AF017079) primer
sequences are: forward primer 5’-TGTACCACCAACT-
GCTTGGC-3’ and reverse primer 5’-GGCATGGACT-
GTGGTCATGAG-3’. Real-time PCRwas performed in an
iCycler iQ real-time PCR detection system. The thermal
cycle condition used for reverse transcription was as fol-
lows: 5 minutes at 25° C, 30 minutes at 42° C, and 5
minutes at 85° C. The condition used for real-time PCR
was as follows: 3minutes at 95° C, 40 repeats of 20 seconds
at 95° C and 1 minute at 60° C. Controls were performed
with no reverse transcription (mRNA sample) or water
control for both eNOS and GAPDH to show the specificity
of the primers and the lack of DNA contamination in
samples. Sample cycle threshold (Ct) values were deter-
mined from plots of relative fluorescence units (RFU) vs
PCR cycle numbers during exponential amplification so
that sample measurement comparisons were possible. The
eNOS gene expression level for each sample was calculated
as 2^(40-Ct). The relative expression for the eNOS in
each sample was normalized against GAPDH, shown as
2[Ct(GAPDH)–Ct(eNOS)].
Western blotting. The protein was isolated from en-
dothelial cells using Tri-Reagent according to the manufac-
turer’s instructions. Cells were then resuspended in 20 L
of 10 M urea and heated for 3 minutes at 100° C. The
protein concentration was determined using the Bradford
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same amount of endothelial protein was resolved electro-
phoretically by one-dimensional SDS-PAGE (10% poly-
acrylamide) for approximately 1 hour at 100 V. Subse-
quently, the gels were equilibrated in transfer buffer (48
mMTris, 39 mM glycine, 0.03% SDS, and 20% methanol),
and the proteins were electrophoretically transferred to
nitrocellulose filters at 100 V for 1 hour on ice. Filters were
blocked using 5% nonfat dried milk in PBS with 0.05%
Tween 20 (PBS-T) for 1 hour at room temperature. eNOS
was detected using a mouse antihuman monoclonal anti-
body diluted 1:1000, and -actin was detected using a
mouse antihuman monoclonal antibody diluted 1:10,000.
The eNOS and -actin primary antibodies were detected
with horseradish peroxidase (HRP)–conjugated goat anti-
mouse immunoglobulin G secondary antibodies diluted
1:5000. Blots were developed using ECL™ plus and ana-
lyzed with an AlphaImager gel documentation system (Al-
pha Innotech Co, San Leandro, CA).
Immunohistochemistry. Rings of treated porcine
coronary arteries were fixed overnight in 10% neutral buff-
ered formalin and subsequently were stored in 70% alcohol
until processing. Samples were later embedded in paraffin,
cut into 5-m-thick cross-sections, and mounted onto
slides. Sections were treated with 3% H2O2 in PBS (pH,
7.4) for 10 minutes to quench the endogenous peroxidase
activity. After three 10-minute rinses in 0.1 M PBS, sec-
tions were incubated in monoclonal antibody against hu-
man eNOS (1:1000) diluted in 0.1 M PBS containing 5%
normal horse serum, 0.1% Triton-X 100 overnight at 4° C.
After another three 10-minute rinses in 0.1 M PBS, sec-
tions were incubated with biotinylated antimouse immu-
noglobulin G (1:250) at room temperature for 40 minutes.
For diaminobenzidine visualization, sections were incu-
bated in avidin-biotin-peroxidase solution at room temper-
ature for 1 hour, followed by 0.1% diaminobenzidine and
0.003% H2O2 in TBS for 5 to 10 minutes. Sections were
counterstained with hematoxylin-eosin, cover-slipped, and
viewed on an Olympus BX41 microscope (Olympus USA
Inc, Melville, NY). Images were captured with an attached
SPOT-RT digital camera and software (Diagnostic Instru-
ments Inc, Sterling Heights, MI).
Lucigenin-enhanced chemiluminescence analysis.
Levels of superoxide anion produced by endothelial cells
were detected using the lucigenin-enhanced chemilumi-
nescence method with Sirius Luminometer and FB12 soft-
ware from Berthold Detection System GmbH (Pforzheim,
Germany). The rings were cut open longitudinally and
trimmed into approximately 5  5–mm pieces. They were
then rinsed briefly in a modified Krebs HEPES buffer
solution (KHBS, 120 mM NaCl, 4.7 mM KCl, 1.18 mM
K2HPO4, 20 mM HEPES, 2.5 mM CaCl2, 1.17 mM
MgSO4, and 25 mM NaHCO3). An assay tube (12  75
mm) was filled with 500 L of Krebs HEPES buffer
solution and 25L of lucigenin. After gently vortexing, the
vessel segments were placed endothelium-side-down in the
tubes. A time-based reading of the luminometer was re-
corded by FB12 software. The data in relative light unitsper second (RLU/sec) for each sample were averaged
between 5 and 10 minutes. Values of blank tubes contain-
ing the same reagents as the vessel ring samples were
subtracted from their corresponding vessel samples. The
area of each vessel segment was measured using a caliper
and was used to normalize the data for each sample. Final
data were represented as RLU/sec/mm2.
Statistical analysis. Data from the different groups
were analyzed using an unpaired Student’s t test (two-tail,
Minitab software, Sigma Breakthrough Technologies Inc,
San Marcos, TX). In addition, an analysis of variance
(ANOVA) test was used to analyze data of endothelium-
dependent relaxation in response to bradykinin. A P value
 0.05 was considered statistically significant. Statistics are
reported as mean  the standard error (SE) of the mean
(SEM).
RESULTS
Rb1 blocks Hcy-induced endothelial vasomotor
dysfunction. The effects of Hcy and Rb1 on the contrac-
tility of pig coronary artery rings are shown in Fig 1. There
was no substantial difference in maximum vessel contrac-
tion in response to U46619 (107 M) among all groups,
including DMSO control, Hcy (50 M) alone, low-dose
Rb1 (1 M) or high-dose Rb1 (10 M) alone, and Hcy
combined with low-dose or high-dose Rb1 (P  .05).
Endothelium-dependent vasorelaxation induced by brady-
kinin was significantly different between the Hcy-treated
group and the controls. As shown in Fig 2, A, precon-
tracted arterial rings in the Hcy-alone group showed a
marked reduction in endothelium-dependent vasorelax-
ation (4.16 3.01%, 14.7 6.94%, 26.8 5.14%, 39.7
3.95%, 49.8  2.49%, respectively) in response to each
cumulative dose of bradykinin (109, 108, 107, 106,
105, respectively) as compared with the DMSO controls
(8.84  2.27%, 24.6  4.01%, 46.7  3.58%, 62.7 
4.68%, 71.8  2.32%, respectively). Additionally, both
low-dose and high-dose Rb1-alone groups showed a simi-
lar vasorelaxation pattern as the control (9.13  5.17%,
22.4  7.67%, 45.1  6.4%, 62.3  38%, 71.3  1.84%;
and 8.8 2.68%, 38 5.69%, 55.3 4.29%, 64.9 3.7%,
72  2.55%, respectively) Furthermore, low-dose Rb1-
Hcy did not show a significant improvement in endotheli-
um-dependent relaxation as compared with Hcy alone,
whereas high-dose Rb1-Hcy completely reversed the effect
of Hcy and showed a similar vasorelaxation pattern as the
control group. Lastly, Fig 2, B shows the vasorelaxation
pattern of each group in response to the high concentration
of bradykinin (105). Endothelium-dependent relaxation
was significantly impaired in rings treated withHcy alone as
compared with the controls (49.80% vs 71.77%, n 8, P
.05), whereas neither high-dose nor low-dose Rb1-alone
affects endothelium-dependent relaxation (71.34  1.84%
and 72  2.55%, respectively). The low-dose Rb1-Hcy
combined group had partially improved endothelium-de-
pendent relaxation (54.44  2.63%), whereas the high-
dose Rb1-Hcy combined group showed complete recovery
of endothelium-dependent relaxation (72.89 2.2%). Our
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endothelium-independent relaxation induced by SNP
among all groups (P  .05) (Fig 3), thus indicating that
smooth muscle NO–dependent cyclic guanosine mono-
phosphate (cGMP)–mediated signaling function remained
intact.
Rb1 improves Hcy-induced impairment of eNOS
mRNA expression. The levels of eNOS mRNA expres-
sion in porcine coronary arteries were measured using
real-time PCR analysis to determine the influences of Hcy
and Rb1 on mRNA expression in the treated arterial rings
(Fig 4). All of the values were normalized with GAPDH,
which served as the internal control. The Hcy-alone group
showed a 46% reduction of eNOS mRNA level (0.013 
0.003) as compared with the DMSO control (0.024 
0.004, P  .05), whereas both the low-dose and the
high-dose Rb1 group had a comparable level of eNOS
mRNA as the controls (0.027 0.001 and 0.024 0.001,
respectively; P .05). In addition, the high-dose Rb1-Hcy
combined group showed a significant improvement in
eNOS mRNA level (0.018 0.002) as compared with the
Hcy-alone group (0.013  0.003, P  .05).
Rb1 counteracts Hcy-induced reduction of eNOS
protein levels. The level of eNOS protein production was
determined by Western blot analysis, and the data were
normalized using the internal loading controls of -actin
(Fig 5). Based on the results from the mRNA data, only the
high-dose Rb1-Hcy combined group had statistically sig-
nificant improvement in the eNOS mRNA level, thus only
high-dose Rb1 was chosen for eNOS protein analysis.
Consistent with the eNOSmRNAdata, Hcy-treated vessels
showed substantially less density of eNOS protein bands
and a 65% reduction in the eNOS protein–-actin ratio
(0.272 0.06) as compared with the control group (0.787
 0.11), and the high-dose Rb1-Hcy combined group
Fig 1. The effects of Hcy and ginsenoside Rb1 on the contractil-
ity of porcine coronary arteries. The rings (n  8 per group) were
cultured in DMSO control, Hcy (50 M) alone, low-dose Rb1 (1
M) or high-dose Rb1 (10 M) alone, and Hcy combined with
low-dose or high-dose Rb1. There is no substantial difference in
maximum vessel contraction in response to U46619 (107 M)
among all groups (n  8, P  .05).showed a significantly improved eNOS protein level (eNOSprotein–-actin ratio, 0.555  0.06, P  .05). The eNOS
protein level in the high-dose Rb1-alone group had no
significant differences as compared with that in the DMSO
control group (P  .05).
eNOS protein expression in porcine coronary arterial
endothelium was further depicted using immunohisto-
chemical staining (Fig 6). The DMSO control group
showed a strong positive staining pattern of eNOS on the
endothelial layer of the arterial walls in contrast to the poor
staining pattern of eNOS in the Hcy-alone group. Again,
only high-dose Rb1 was used for comparison and showed
similar staining patterns as the DMSO controls. Impor-
tantly, the high-dose Rb1-Hcy combined group showed a
Fig 2. The effects of Hcy and GS Rb1 on the endothelium-
dependent vasorelaxation induced by bradykinin. A, Vasorelax-
ation in response to cumulative doses of bradykinin showing
improved vasorelaxation among all groups as the concentration of
bradykinin increases. The high-dose Rb1-Hcy group showed sig-
nificant improvement in vasorelaxation compared with Hcy alone
at the bradykinin concentrations of 107, 106, and 105 M. B,
Vasorelaxation in response to the highest dose of bradykinin (105
M). The Hcy and low-dose Rb1-Hcy groups showed significant
impairments in vasorelaxation compared with the control (n 8, P
 .05), whereas the high-dose Rb1-Hcy group showed significant
improvement in vasorelaxation compared with Hcy (n  8, P 
.01) and similar to the control group.strong positive staining pattern similar to that of the control
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endothelial layer of the high-dose Rb1-Hcy group.
Rb1 attenuates Hcy-induced superoxide anion
production. Levels of superoxide anion produced by en-
dothelial cells were determined using lucigenin-enhanced
chemiluminescence (Fig 7). Superoxide anion was mark-
edly increased by 137% in Hcy treated groups as shown by
significantly higher levels of peak chemiluminescence (17.5
 5.4 RLU/s/mm2, n  8) than the DMSO controls
(8.75  1.72 RLU/s/mm2, n  8). High-dose or low-
dose Rb1 alone showed no effects on the level of peak
chemiluminescence as compared with the controls (7.09
0.84, 8.93  1.4, 8.75  1.72 RLU/s/mm2, respec-
tively). Again, both high-dose and low-dose Rb1-Hcy
combined groups showed a substantial reduction in super-
Fig 3. The effects of Hcy and GS Rb1 on endothelium-indepen-
dent relaxation as compared with the DMSO control. There is no
significant difference among all groups (n  8, P  .05) in the
endothelium-independent vasorelaxation induced by SNP.
Fig 4. The influence of Hcy and GS Rb1 on mRNA expression in
the treated arterial rings. The levels of eNOS mRNA expression in
porcine coronary arteries were measured using real-time PCR
analysis. The relative expression for the eNOS in each sample was
normalized against GAPDH, shown as 2^[Ct(GAPDH)–Ct(eNOS)].
The Hcy-alone group showed a significant reduction in eNOS
mRNA level compared with control (n  6, P  .05), and Rb1
(high-dose) significantly improved eNOS mRNA level in the Rb1-
Hcy groups (n  6, P  .05).oxide anion level as shown by a dramatically decreased levelof peak chemiluminescence (9.22  1.4 and 9.34  0.28
RLU/s/mm2, respectively).
DISCUSSION
Although ginseng and its active constituents, ginsen-
osides, have gained increased popularity worldwide for a
myriad of beneficial effects, the underlying mechanisms are
still unclear. The information regarding the effects of gin-
seng on cardiovascular diseases is even more scattered.
Herein we investigated the cellular mechanism as well as
the functional influence of ginsenoside Rb1 on protecting
against Hcy-induced endothelial damage. This study
showed that Rb1 prevented Hcy-induced impairment of
endothelium-dependent vasorelaxation and improved
Hcy-induced reduction of eNOS production. To our
knowledge, this is the first study that shows the beneficial
role of ginsenoside in preventing Hcy-induced vascular
injury in porcine coronary arteries and shows the potential
underlying mechanisms of interaction between ginsenoside
and Hcy on endothelium. Our results suggest the potential
clinical application of ginseng and its major constituents in
protecting the endothelium against Hcy and superoxide-
associated injuries, thus having a potential role in cardio-
vascular disease prevention.
Hcy is a known risk factor for cardiovascular disease.
Severe hyperhomocysteinemia (100 M) has been ob-
served in patients with homozygous deficiency of cystathi-
onine -synthase or methylene tetrahydrofolate reductase
and is usually associated with premature arthrosclerosis or
thrombosis. Even a mild to moderate elevation of Hcy (10
to 100M) is associated with increased risks for cardiovas-
Fig 5. The level of eNOS protein production determined by
Western blot analysis after being normalized with -actin as an
internal control. Hcy significantly impaired eNOS protein level
compared with the control (P .01), and the high-dose Rb1-Hcy
combined group showed statistically significant improvement in
eNOS protein levels as compared with the Hcy-alone group (n 
3, P  .05).cular and cerebrovascular diseases. A study from our labo-
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um-dependent vasorelaxation and eNOS immunoreactivity
as well as induced marked endothelial injury in both por-
cine coronary and carotid arteries.5 Additionally, Eberhardt
and colleagues showed that mild hyperhomocysteinemia
impaired endothelium-dependent vasodilatation by in-
creasing reactive oxygen species, and a subsequent losing of
NO bioavailability in an animal model.14 Furthermore,
Lang et al confirmed that the inhibitory effect of Hcy on
endothelium-dependent relaxation is caused by an increase
Fig 6. Immunohistochemical staining of eNOS protein expres-
sion in porcine coronary arterial endothelium. A, DMSO control
group showing a strong positive staining pattern of eNOS on the
endothelial layer of the arterial walls. B,Hcy-alone group showing
poor staining pattern of eNOS. C, High-dose Rb1-alone group,
and D, high-dose Rb1-Hcy combined group showing a strong
positive staining pattern similar to that of the control group.
Fig 7. Levels of superoxide anion produced by endothelial cells
using the lucigenin-enhanced chemiluminescence. Superoxide an-
ion was markedly increased in Hcy-treated groups compared with
DMSO control (n  6, P  .01). High-dose or low-dose Rb1
alone showed no effects on the level of peak chemiluminescence as
compared with the control. Both high-dose and low-dose Rb1-
Hcy combined groups showed a substantial reduction in superox-
ide anion levels.in the endothelial cell intracellular levels of superoxide.15Lastly, Tawakol et al studied human brachial artery dilata-
tion during reactive hyperemia in subjects with hyperho-
mocysteinemia and proved that endothelium-dependent
vasodilatation was significantly impaired in the hyperhomo-
cysteinemic subjects as compared with control subjects,
whereas endothelium-independent vasodilatation was no
different between the two groups.16 However, Tasatargil et
al documented that short-term exposure to Hcy signifi-
cantly decreased vascular responsiveness in human internal
mammary arteries through other mechanisms, including
possible Ca		 channel involvement and other undefined
direct effects.17 Based on our previous study,5 a Hcy con-
centration of 50 M (mild to moderate hyperhomocys-
teinemia) was chosen to induce impairment on endotheli-
um-dependent relaxation without affecting endothelium-
independent relaxation or smooth muscle contraction.
Studies have shown that ginseng and ginsenosides in-
duce NO release, a primary vasodilator. Chen et al showed
the relaxation effects of ginsenoside Rb1 and Rg1 on
pulmonary vessels.18 However, Kang et al studied the
effects of two different groups of ginsenosides, proto-
panaxatriol (Rg1 and Re) and protopanaxadiol (Rb1 and
Re), on rat aortic rings.19 They indicated that ginsenosides
from the protopanaxatriol group, but not the protopanax-
adiol group, enhanced the release of NO from endothelial
cells. Other endothelium-derived vasomotor factors have
also been shown to be involved in vasorelaxation. Fang et al
studied myocardial infarction and reperfusion on a dog
model and discovered that ginsenoside decreased throm-
boxane A2 and increased 6-keto PGF1 levels after both
coronary occlusion and reperfusion, which confirmed the
protective effects of ginsenosides through vasomotor fac-
tors.20 Yuan et al also studied the effects of ginseng extracts
on human umbilical vein endothelial cells and showed that
ginseng extracts inhibited thrombin-induced endothelin
release, a potent vasoconstrictor.21 Kim et al showed that
ginsenoside Rg3 mediated endothelium-dependent relax-
ation through eNOS activation in rat arteries.22 Kwan et al
showed that ginseng extracts induced endothelium-depen-
dent vasorelaxation through a mechanism of activation of
the eNOS system in both dog and rat arteries.23 However,
our study focused on the blocking effect of ginsenoside
Rb1 on Hcy-induced endothelium dysfunction. Our data
suggest that Rb1 effectively blocks the effect of Hcy
through maintaining eNOS functions and reducing oxida-
tive stress. Based on our knowledge, this is the first report
that ginsenoside Rb1 counteracts the effects of Hcy.
Results on homocysteine-induced vasomotor dysfunc-
tion from this study are consistent with previous studies
from our laboratory in showing that Hcy significantly im-
pairs the endothelium-dependent relaxation that was in-
duced by cumulative doses of bradykinin, and exerted no
effect on maximal contraction or endothelium-indepen-
dent relaxation induced by thromboxin analog and SNP,
respectively.11,12 Furthermore, our study investigated the
effects of ginsenoside Rb1 on Hcy-associated vasomotor
dysfunction, showing that Rb1 by itself had no effect on
vasomotor function of porcine coronary arterial rings.
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combined group had a complete recovery of endothelium-
dependent vasorelaxation and a low-dose Rb1-Hcy group
had only a partial improvement in vasorelaxation. Although
the low-dose Rb1-Hcy combined group apparently had
decreased endothelium-dependent relaxation beyond the
reduction seen with Hcy alone at low concentrations of
bradykinin, the reduction was not statistically significant.
We believe that fluctuations in the values may be caused by
the variability of tissue samples and native conditions of the
porcine coronary arteries. In addition, our results of Rb1
alone having no effect on vasomotor function is consistent
with the study by Kang et al, who showed that ginsenosides
in a protopanaxadiol group, including Rb1, do not enhance
NO release from endothelial cells,18 although a study from
Chen et al concluded otherwise.18 From the vasomotor
study, we postulate that Rb1 dose-dependently blocks
Hcy-induced impairment of endothelium-dependent va-
sorelaxation, which indicates a potential clinical application
of Rb1 in preventing Hcy-induced vascular dysfunction.
Molecular mechanisms of Hcy-induced endothelium
dysfunction have been extensively studied. Oxidative stress
and eNOS reduction have proven to be the major mecha-
nisms through which Hcy exerts its effects on vascular
endothelium. Eberhardt et al showed that an increased
superoxide production is associated with Hcy-induced en-
dothelium damage in a mouse model.14 Additionally, our
previous study showed that Hcy suppressed eNOS immu-
noactivity, and thus induced endothelium dysfunction.5
Moreover, Li et al used a complementary DNA microarray
to disclose a link between Hcy and cholesterol dysregula-
tion, and showed the possible role of Hcy-induced oxida-
tive stress in this response.24 Lastly, Pruefer et al examined
the acute effect of homocysteine on endothelial dysfunc-
tion in isolated rat arteries and on microcirculatory leuko-
cyte-endothelium interaction in vivo.25 They concluded
that acute hyperhomocysteinemia induces endothelial dys-
function, characterized by a loss of endothelium-derived
NO, leading to an inflammatory state. We investigated the
molecular mechanisms of Hcy-induced endothelial dys-
function by studying eNOSmRNA and protein production
using real-time PCR and Western blot. Because Hcy may
cause injury and loss of endothelial cells, we have used
internal controls to ensure an equal amount of tissue sam-
ples for the study among all groups. Total RNA or proteins
were measured before real-time PCR or Western blot was
performed. The housekeeper gene GAPDHwas used as the
control in real-time PCR analysis, and -actin was used as
the internal control for Western blot. All of the values were
normalized before final analysis. The Hcy-treated group
showed a marked reduction of eNOS mRNA and protein
levels as compared with the control group. Additionally,
decreased eNOS expression in the porcine coronary arterial
endothelium was depicted by immunohistochemical stain-
ing, which was consistent with Western blot results. Fur-
thermore, the fact that high-dose Rb1 completely reversed
the adverse effects of Hcy on endothelial cells with no
significant effects on the eNOS level when incubated withporcine coronary rings alone implies that Rb1 was protect-
ing the endothelium from Hcy-induced damage with little
effect on the healthy endothelium. However, the changes
in NO levels of Hcy- or Rb1-treated vessels were not
studied. It could be interesting to measure eNOS activity
by the conversion of arginine to citulline and NO produc-
tion.
Free radicals have been shown to play a key role in
atherosclerotic plaque formation and to be involved in
various vascular injuries. Extensive studies have been con-
ducted on the protective effects of ginseng against free-
radical damage on the vascular endothelium. Zhong et al
examined cellular structures of free radical damage on
myocardial cells induced by xanthine. They measured free
radicals with an electron spin resonance technique and
discovered certain ginsenosides (Rb1, Rb2, Rb3, Rc, Rg1,
Rg2, Re, and Rh1) counteracting the action of free radicals
induced by xanthine.26 In an animal model, Chen et al
showed that ginsenoside protected against myocardial
reperfusion injury with a concomitant increase in 6-keto-
PGF1a and a decrease in lipid peroxidation, and also pro-
tected the rabbit pulmonary and aortic endothelium against
electrolysis-induced free radical damage.18 Additionally,
Gillis showed the protective effects of ginsenoside on an
injured rabbit pulmonary endothelium induced by a variant
of reactive oxygen species.9 He further reviewed other
studies and confirmed that ginseng prevented manifesta-
tions of oxygen-derived free radical injury by promoting
the release of NO. In our study, Hcy-induced free radical
production and the effect of Rb1 were investigated using
lucigenin-enhanced chemiluminescence. We showed that
the Hcy-treated group had a significant increase in free
radical production, whereas Rb1 blocked the effect of Hcy,
as indicated by dramatically decreasing levels of peak
chemiluminescence in Rb1-Hcy combined groups. Our
study proved that either high-dose or low-dose Rb1 fully
blocked free radical production.
Admittedly, mechanisms of Hcy-induced endothelial
damages have not yet been fully elucidated. Our results
indicated that other cellular pathways may be involved in
the functional effects of Hcy that are not influenced by
Rb1. As shown by our data, both low-dose and high-dose
Rb1 completely reversed superoxide anion production in-
duced by Hcy in Hcy-Rb1 combined groups, whereas
low-dose Rb1 only partially recovered the eNOS mRNA
level and endothelial-dependent relaxation. Furthermore,
our data suggested that ginsenoside Rb1 functions in a
dose-dependent manner, thus low-dose Rb1 may not be
enough to overcome the adverse effects induced by Hcy.
Further studies are warranted to explore the detailed mo-
lecular and cellular mechanisms of Rb1. It is interesting to
compare the antioxidative effect of Rb1 with a well-known
antioxidant enzyme superoxide dismutase. Tissue-model-
based analysis is limited because of the rapid deterioration
of the endothelial cells and the variable conditions of each
porcine coronary artery. Therefore, to overcome the lim-
ited viability and great variability of tissue samples, a cell
culture model has been created in our laboratory to further
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show that different constituents of ginseng may have an-
tagonistic actions.27 This indicates a more complex inter-
action with more detailed studies required in the future.
In summary, our study showed that ginsenoside Rb1
effectively blocks Hcy-induced impairment of endothelium
vasomotor function in porcine coronary arteries. In addi-
tion, Rb1 successfully improved Hcy-induced reduction of
eNOS expression, and reduced Hcy-induced oxidative
stress. This is the first study that has shown the functional
relationship and molecular mechanisms of the effects of
ginsenoside Rb1 on Hcy-induced endothelial dysfunction.
However, the observations made during this investigation
do not directly translate into human arteries, and there is
extremely limited study in the literature regarding serum
levels of ginsenosides after oral ginseng doses in human.
Therefore, future clinical studies are warranted to deter-
mine the effects of Rb1 on human endothelium and to
determine the optimal oral dose of ginsenoside Rb1 and
ginseng. Consistent with our previous studies,11,12 ginsen-
oside Rb1, similar to red wine and estrogen, effectively
reduces Hcy-induced endothelial dysfunction and free rad-
ical production. These studies imply an important future
therapeutic strategy of using antioxidant-based pharmaco-
therapy in counteracting the detrimental effects of hyper-
homocystinemia. Moreover, the antioxidant-based phar-
macotherapy perhaps also has a protective role in other
free-radical-induced vascular injuries.
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